As of Aug 28
| -0.80 / -0.26%|
The 17 analysts offering 12-month price forecasts for Biogen have a median target of 400.00, with a high estimate of 494.00 and a low estimate of 291.00. The median estimate represents a +31.71% increase from the last price of 303.69.
The current consensus among 23 polled investment analysts is to Buy stock in Biogen. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.